InvestorsHub Logo

sokol

11/08/20 11:41 AM

#525 RE: RedShoulder #524

Unfortunately, this thumb’s down vote is not binding. The FDA could still approve aducanumab:

“The nonbinding vote by an advisory panel for the Food and Drug Administration does not mean the agency won’t approve the drug, aducanumab, made by Biogen. But it signals that many experts in the field are not convinced of its effectiveness, another major setback in the long journey to find a treatment for Alzheimer’s that works.”

https://www.nytimes.com/2020/11/06/health/aducanumab-alzheimers-drug-fda-panel.html

Master Stocktrader

01/16/21 12:37 PM

#536 RE: RedShoulder #524

Cerebain Biotech is priced at 0.12.
If they succeed the Alzheimer approval.
Better priced than Biogen....
Who will winn the Alzheimer medicin....
Imo cbbt a once in a lifetime chance...